Abstract
Background: Attacks of hereditary angioedema with C1 inhibitor deficiency (C1-INH-HAE) are commonly treated in the emergency department. Self-administration is emerging as an effective treatment option. In this study, we assessed the impact of home therapy with plasma-derived C1 esterase inhibitor (pdC1-INH) concentrate on treatment outcomes and costs. Methods: This is an observational study in C1-INH-HAE patients who switched to home therapy with pdC1-INH (Berinert®) after learning intravenous self-infusion in a training course at a center in Southern Italy. Before starting home therapy and after the first year of home therapy, patients were interviewed about their treatment and outcomes during the prior 12 months. Annual costs were analyzed by cost minimization from the Italian health care payer perspective and the societal perspective. Outcomes and costs before and after the switch to home therapy were compared. Results: The training course was attended by 36 participants, 17 (47.2%) of whom decided to switch to home therapy. This therapy was associated with a significant decrease in the mean annual number of hospitalizations (16.8 vs. 2.1, p = 0.003) and missed work/school days (20.3 vs. 7.1, p = 0.037) compared to conventional treatment. The times from symptom onset to treatment administration and from treatment administration to symptom improvement/resolution were not significantly different between the two strategies. The mean annual per-patient costs decreased with home therapy from EUR 30,010.57 to EUR 26,621.16 (11.3% saving) and from EUR 29,309.34 to EUR 26,522.04 (9.5% saving) from the societal and payer perspective, respectively. Conclusions: Home therapy with pdC1-INH is a feasible strategy for the management of C1-INH-HAE and may result in cost savings.
References
1.
Cicardi M, Aberer W, Banerji A, Bas M, Bernstein JA, Bork K, Caballero T, Farkas H, Grumach A, Kaplan AP, Riedl MA, Triggiani M, Zanichelli A, Zuraw B: Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group. Allergy 2014;69:602-616.
2.
Longhurst H, Cicardi M: Hereditary angio-oedema. Lancet 2012;379:474-481.
3.
Bygum A: Hereditary angio-oedema in Denmark: a nationwide survey. Br J Dermatol 2009;161:1153-1158.
4.
Ghazi A, Grant JA: Hereditary angioedema: epidemiology, management, and role of icatibant. Biologics 2013;7:103-113.
5.
Roche O, Blanch A, Caballero T, Sastre N, Callejo D, Lopez-Trascasa M: Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol 2005;94:498-503.
6.
Zanichelli A, Arcoleo F, Barca MP, Borrelli P, Bova M, Cancian M, Cicardi M, Cillari E, De Carolis C, De Pasquale T, Del Corso I, Cesinaro Di Rocco P, Guarino MD, Massaro I, Minale P, Montinaro V, Neri S, Perricone S, Pucci S, Quattrocchi P, Rossi O, Triggiani M, Zanierato G, Zoli A: A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis 2015;10:11.
7.
Aygören-Pürsün E, Bygum A, Beusterien K, Hautamaki E, Sisic Z, Wait S, Boysen HB, Caballero T: Socioeconomic burden of hereditary angioedema: results from the hereditary angioedema burden of illness study in Europe. Orphanet J Rare Dis 2014;9:99.
8.
Nordenfelt P, Dawson S, Wahlgren CF, Lindfors A, Malbris L, Björkander J: Quantifying the burden of disease health state in patients with hereditary angioedema in Sweden. Allergy Asthma Proc 2014;35:185-90.
9.
Wilson DA, Bork K, Shea EP, Rentz AM, Blaustein MB, Pullman WE: Economic costs associated with acute attacks and long-term management of hereditary angioedema. Ann Allergy Asthma Immunol 2010;104:314-320.
10.
Tilles SA, Borish L, Cohen JP: Management of hereditary angioedema in 2012: scientific and pharmacoeconomic perspectives. Ann Allergy Asthma Immunol 2013;110:70-74.
11.
Cicardi M, Bellis P, Bertazzoni G, Cancian M, Chiesa M, Cremonesi P, Marino P, Montano N, Morselli C, Ottaviani F, Perricone R, Triggiani M, Zanichelli A: Guidance for diagnosis and treatment of acute angioedema in the emergency department: consensus statement by a panel of Italian experts. Intern Emerg Med 2014;9:85-92.
12.
Zilberberg MD, Nathanson BH, Jacobsen T, Tillotson G: Descriptive epidemiology of hereditary angioedema hospitalizations in the United States, 2004-2007. Allergy Asthma Proc 2011;32:248-254.
13.
Cicardi M, Craig TJ, Martinez-Saguer I, Hebert J, Longhurst HJ: Review of recent guidelines and consensus statements on hereditary angioedema therapy with focus on self-administration. Int Arch Allergy Immunol 2013;161(suppl 1):3-9.
14.
Bork K, Steffensen I, Machnig T: Treatment with C1-esterase inhibitor concentrate in type I or II hereditary angioedema: a systematic literature review. Allergy Asthma Proc 2013;34:312-327.
15.
Boysen HB, Bouillet L, Aygoren-Pursun E: Challenges of C1-inhibitor concentrate self-administration. Int Arch Allergy Immunol 2013;161(suppl 1):21-25.
16.
Caballero T, Sala-Cunill A, Cancian M, Craig TJ, Neri S, Keith PK, Boccon-Gibod I, Bethune C, Bork K: Current status of implementation of self-administration training in various regions of Europe, Canada and the USA in the management of hereditary angioedema. Int Arch Allergy Immunol 2013;161(suppl 1):10-16.
17.
Longhurst HJ, Farkas H, Craig T, Aygoren-Pursun E, Bethune C, Bjorkander J, Bork K, Bouillet L, Boysen H, Bygum A, Caballero T, Cicardi M, Dempster J, Gompels M, Gooi J, Grigoriadou S, Huffer U, Kreuz W, Levi MM, Long J, Martinez-Saguer I, Raguet M, Reshef A, Bowen T, Zuraw B: HAE international home therapy consensus document. Allergy Asthma Clin Immunol 2010;6:22.
18.
Bygum A, Andersen KE, Mikkelsen CS: Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol 2009;19:147-151.
19.
Kreuz W, Rusicke E, Martinez-Saguer I, Aygoren-Pursun E, Heller C, Klingebiel T: Home therapy with intravenous human C1-inhibitor in children and adolescents with hereditary angioedema. Transfusion 2012;52:100-107.
20.
Levi M, Choi G, Picavet C, Hack CE: Self-administration of C1-inhibitor concentrate in patients with hereditary or acquired angioedema caused by C1-inhibitor deficiency. J Allergy Clin Immunol 2006;117:904-908.
21.
Bork K, Meng G, Staubach P, Hardt J: Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005;45:1774-1784.
22.
Rizk C, Karsh J, Santucci S, Yang W: Self-administration of intravenous C1 esterase inhibitor in hereditary angioedema. CMAJ 2013;185:791-792.
23.
Craig TJ. Recent advances in hereditary angioedema self-administration treatment: summary of an international hereditary angioedema expert meeting. Int Arch Allergy Immunol 2013;161(suppl 1):26-27.
24.
Symons C, Rossi O, Magerl M, Andritschke K: Practical approach to self-administration of intravenous C1-INH concentrate: a nursing perspective. Int Arch Allergy Immunol 2013;161(suppl 1):17-20.
25.
SPC icatibant. 2013. http://www.ema.Europa.Eu/docs/en_gb/document_library/epar_-_product_information/human/000899/wc500022966.Pdf (accessed June 12, 2014).
26.
SPC Berinert. 2013. https://www.Medicines.Org.Uk/emc/medicine/21650/spc/berinert+500+iu/ (accessed June 12, 2014).
27.
Decreto ministeriale del 18/10/2012. http://www.Crob.It/crob/files/docs/10/63/33/document_file_106333.Pdf (accessed June 12, 2014).
28.
Decreto del commissario ad acta No 32 del 27/03/13. http://www.Arsan.Campania.It/documents/10157/2fa38e7f-28c4-470e-b7c0-3fef24b080ac (accessed June 12, 2014).
29.
Determinazione No 57 del 17 giugno 2013. http://www.Soresa.It (accessed June 12, 2014).
30.
ACI. 2014. http://servizi.Aci.It/ckinternet/selezionemodello (accessed June 12, 2014).
31.
ISTAT: Struttura delle retribuzioni 2010. 2013. http://www.Istat.It/it/archivio/83362 (accessed June 12, 2014).
32.
Allen DW: An alternative method for assessing the value of housewife services. 2004. http://www.economica.ca/ew09_1p2.htm (accessed June 12, 2014).
33.
OECD: Education at a glance 2012: OECD indicators. 2012.http://www.oecd.org/edu/EAG%202012_e-book_EN_200912.pdf (last accessed June 12, 2014).
34.
Bygum A: Hereditary angioedema - consequences of a new treatment paradigm in Denmark. Acta Derm Venereol 2014;94:436-441.
35.
Gregory C, Landmesser LM, Corrigan L, Mariano D: Feasibility of home infusion and self-administration of nanofiltered C1 esterase inhibitor for routine prophylaxis in patients with hereditary angioedema and characterization of a training and support program. J Infus Nurs 2014;37:29-34.
36.
Rusicke E, Martinez-Saguer I, Aygören-Pürsün E, Kreuz F: Home treatment in patients with hereditary angioedema (HAE) (abstract). J Allergy Clin Immunol 2006;117:S180.
37.
Tuong LA, Olivieri K, Craig TJ. Barriers to self-administered therapy for hereditary angioedema. Allergy Asthma Proc 2014;35:250-254.
38.
Tourangeau LM, Castaldo AJ, Davis DK, Koziol J, Christiansen SC, Zuraw BL: Safety and efficacy of physician-supervised self-managed C1 inhibitor replacement therapy. Int Arch Allergy Immunol 2012;157:417-424.
39.
Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angioedema. Allergy 2008;63:751-757.
40.
Maurer M, Aberer W, Bouillet M, Caballero T, Fabien V, Kanny G, Kaplan A, Longhurst H, Zanichelli A; IOS Investigators: Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 2013;8:e53773.
41.
Abdel-Karim O, Dizdarevic A, Bygum A: Hereditary angioedema: children should be considered for training in self-administration. Pediatr Dermatol 2014;31:e132-135.
42.
Blasco AJ, Lazaro P, Caballero T, Guilarte M: Social costs of icatibant self-administration vs. health professional-administration in the treatment of hereditary angioedema in Spain. Health Econ Rev 2013;3:2.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
